| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/01/2002 | US20020102261 Immunological control of beta-amyloid levels in vivo |
| 08/01/2002 | US20020102254 For diagnostic and therapeutic uses in cancer |
| 08/01/2002 | US20020102253 For use as anti-cancer agent and an immunosuppressive agent |
| 08/01/2002 | US20020102232 Compositions and methods for induction of active autoimmunity |
| 08/01/2002 | DE10101430A1 Lösliche cyclische Analoga Soluble cyclic analogues |
| 08/01/2002 | CA2792244A1 A method for identification, isolation and production of antigens to a specific pathogen |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2436091A1 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 08/01/2002 | CA2435949A1 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | CA2435776A1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | CA2435672A1 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | CA2435568A1 Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
| 08/01/2002 | CA2435097A1 Peptides exibiting affinity for the viral protein gp120, and use of the se peptides |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2433681A1 Sulfatases and methods of use thereof |
| 08/01/2002 | CA2433227A1 Specific human antibodies for selective cancer therapy |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2431313A1 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2431144A1 Cell adhesion proteins |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2425506A1 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 07/31/2002 | EP1227324A2 Har A polypeptides and nucleic acids and related methods and uses thereof |
| 07/31/2002 | EP1227323A1 Non-A, non-B hepatitis virus antigen, diagnostic methods and vaccines |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226433A1 Method for identifying active anti-apoptosis compounds |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226264A2 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus |
| 07/31/2002 | EP1226263A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 07/31/2002 | EP1226256A1 Recombinant therapeutic fusion proteins |
| 07/31/2002 | EP1226254A2 Virulence genes, proteins, and their use |
| 07/31/2002 | EP1226253A2 Neisserial antigenic peptides |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226250A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 07/31/2002 | EP1226248A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 07/31/2002 | EP1226243A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 07/31/2002 | EP1226238A2 Method for creating divergent populations of nucleic acid molecules and proteins |
| 07/31/2002 | EP1226235A2 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 07/31/2002 | EP1226178A1 Recombinant fusion molecules |
| 07/31/2002 | EP1226177A2 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 07/31/2002 | EP1226176A1 Production of mammary secretion antibodies in farm animals |
| 07/31/2002 | EP1226169A2 Molecular structure of rhd negative locus |
| 07/31/2002 | EP1226167A1 Modified peptides and peptidomimetics for use in immunotherapy |
| 07/31/2002 | EP1226166A1 Immuno-interactive fragments of the alpha c subunit of inhibin |
| 07/31/2002 | EP1226161A2 Apo-2 receptor antibodies |
| 07/31/2002 | EP1226152A2 Regulation of gene expression by neuroleptic agents |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1225920A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225914A2 A method to improve protective immunity induced by polynucleotide vaccines |
| 07/31/2002 | EP1225912A1 A method of prophylaxis and treatment |
| 07/31/2002 | EP1225910A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 07/31/2002 | EP1225909A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 07/31/2002 | EP1225907A1 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
| 07/31/2002 | EP1225870A1 Composition and method of cancer antigen immunotherapy |
| 07/31/2002 | EP1225801A1 Propagation of human hepatocytes in non-human animals |
| 07/31/2002 | EP1049490B1 Method for inhibiting cd95-independent apoptosis in aids |
| 07/31/2002 | EP0850244B1 Toxoplasma gondii glycoconjugates |
| 07/31/2002 | EP0825873B1 Anticancer vaccine comprising il6/il6 receptor transfected cells |
| 07/31/2002 | EP0708656B1 Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| 07/31/2002 | EP0700297B1 Surrogate tolerogenesis for the development of tolerance to xenografts |
| 07/31/2002 | EP0583356B1 A method for treating infectious respiratory diseases |
| 07/31/2002 | CN1361865A Catalytic anti-factor VIII allo-antibodies |
| 07/31/2002 | CN1361825A Novel antifungal agents and fungicides method for the production thereof and their use |
| 07/31/2002 | CN1361824A Porcine circovirus recombinant poxvirus vaccine |
| 07/31/2002 | CN1361700A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 07/31/2002 | CN1361181A New human chorionic gonadotropin-lutropin fusion protein and its prepn and use |
| 07/31/2002 | CN1360948A Prepn of deactivated dual vibrio vaccine for sea fish |
| 07/31/2002 | CN1360947A Moulds refining and enriching process |
| 07/30/2002 | US6426405 Therapeutic target for treatment of diseases associated with altered muscle activity of pain transmission; has properties of glycine transporter associated with strychnine sensitive glycine receptors--properties called ?sc6? activity |
| 07/30/2002 | US6426336 Method for treating allergic lung disease |
| 07/30/2002 | US6426224 Biosynthesis, mixing |
| 07/30/2002 | US6426217 MAGE-3 peptides presented by HLA class II molecules |
| 07/30/2002 | US6426203 Attenuated strains of Leishmania and uses thereof |
| 07/30/2002 | US6426196 Alphavirus structural protein expression cassettes |
| 07/30/2002 | US6426097 Herbal supplement for cognitive related impairment due to estrogen loss |
| 07/30/2002 | US6426088 Sustained release; in situ insertion |
| 07/30/2002 | US6426074 Preventing infections |
| 07/30/2002 | US6426073 Genetic engineered polypeptides |
| 07/30/2002 | CA2369405A1 Har a polypeptides and nucleic acids, and related methods and uses thereof |
| 07/30/2002 | CA2084673C 16 kda surface protein of p.falciparum |
| 07/30/2002 | CA2039230C Monoclonal antibodies that inhibit growth of kaposi's sarcoma |
| 07/30/2002 | CA2029201C Process for purifying b pertussis antigens |
| 07/25/2002 | WO2002057784A2 Chlamydia heat shock protein |
| 07/25/2002 | WO2002057741A2 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| 07/25/2002 | WO2002057465A2 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | WO2002057453A2 Polypetides and nucleic acids encoding same |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057419A2 Protein-protein interactions |
| 07/25/2002 | WO2002057314A2 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |
| 07/25/2002 | WO2002057306A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | WO2002057303A2 Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides |
| 07/25/2002 | WO2002057302A2 A virus causing respiratory tract illness in susceptible mammals |
| 07/25/2002 | WO2002056910A1 Binding domain-immunoglobulin fusion proteins |
| 07/25/2002 | WO2002056909A2 Method for inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsids |
| 07/25/2002 | WO2002056908A2 Artificial antigen-presenting cells |